Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve ...
"Eisai and Biogen’s Leqembi sBLA set for Alzheimer’s maintenance dosing" was originally created and published by ...
The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's ...
Eisai and Biogen have secured US Food and Drug Administration approval for a once-monthly intravenous maintenance dosing ...
Seeking Alpha on MSN6d
Biogen, Eisai Alzheimer’s drug review delayed in EUBiogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.
Eisai and Biogen update on lecanemab's EU regulatory ... obligation to publicly update any forward-looking statements. The Pharma Letter. 2024. BRIEF-Mexican approval for Alzheimer’s drug ...
Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...
The monthly maintenance regimen, which offers a more convenient frequency than the initially approved treatment schedule for ...
The Japanese and American based pharma companies announced a win for their Alzheimer’s treatment, which has faced some negative backlash over the last year.
RFK Jr. faces unified opposition for HHS post; Trump disrupts NIH proceedings; Biogen CEO tells Mass. Gov there is “policy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback